U.S. Markets open in 58 mins

NeuroPace, Inc. (NPCE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.10-1.05 (-17.07%)
At close: 04:00PM EDT

NeuroPace, Inc.

455 North Bernardo Avenue
Mountain View, CA 94043
United States
650 237 2700

IndustryMedical Devices
Full Time Employees166

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael L. FavetPres, CEO & Director835.42kN/A1970
Ms. Irina RidleyGen. Counsel & Corp. Sec.462.11kN/A1986
Dr. Martha J. MorrellChief Medical Officer583.5kN/A1957
Ms. Rebecca L. KuhnCFO, VP of Fin. & Admin. and Assistant Sec.N/AN/A1961
Ms. Chi NguyenVP of MarketingN/AN/A1977
Mr. Mark S. SaxtonVP of SalesN/AN/A1965
Ms. Irene ThomasVP of HRN/AN/A1969
Mr. Andre G. MarquetteChief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Corporate Governance

NeuroPace, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.